Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Shares Outstanding for 15 consecutive years, with $28.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding rose 2.33% year-over-year to $28.1 million, compared with a TTM value of $28.1 million through Sep 2025, up 2.33%, and an annual FY2024 reading of $27.5 million, up 1.85% over the prior year.
  • Shares Outstanding was $28.1 million for Q3 2025 at Fennec Pharmaceuticals, up from $27.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $28.1 million in Q3 2025 and bottomed at $26.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $26.8 million, with a median of $26.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding soared 30.69% in 2021, then increased 0.14% in 2022.
  • Year by year, Shares Outstanding stood at $26.0 million in 2021, then rose by 1.36% to $26.4 million in 2022, then grew by 2.53% to $27.0 million in 2023, then rose by 1.85% to $27.5 million in 2024, then grew by 1.94% to $28.1 million in 2025.
  • Business Quant data shows Shares Outstanding for FENC at $28.1 million in Q3 2025, $27.7 million in Q2 2025, and $27.6 million in Q1 2025.